The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for ...

Zacks Research has upped the financial bar for Vertex Pharmaceuticals, boosting its 2026 earnings forecast from $16.18 to $16 ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

Learn more about whether CRISPR Therapeutics AG or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ ...

Vertex Pharmaceuticals earned well-deserved kudos after Dr. Paul Negulescu snagged the 2025 Canada Gairdner International ...

The problem for investors is that Trump in his Oval Office comments referred to pharmaceutical tariffs of “50% or 100% or 200 ...

Canada Gairdner Awards recognize the world’s most accomplished researchers whose work is improving our understanding of human ...

On CNBC's “Halftime Report Final Trades ,” Joshua Brown of Ritholtz Wealth Management picked CrowdStrike Holdings, Inc. CRWD.

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Learn more about whether Moderna, Inc. or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.